Trial Outcomes & Findings for Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy (NCT NCT00848354)
NCT ID: NCT00848354
Last Updated: 2016-01-18
Results Overview
ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of the Health Assessment Questionnaire; HAQ); and C-Reactive Protein (CRP).
COMPLETED
PHASE4
429 participants
Week 24
2016-01-18
Participant Flow
The study consisted of 3 periods - Phase 1 (week 0-week 24), Phase 2 Year 1 (week 24-week 76), and Phase 2 Year 2 (week 76-week 128). 429 participants were randomly assigned to open label etanercept + methotrexate or open label conventional disease-modifying antirheumatic drug (DMARD) + methotrexate in a 2:1 allocation, respectively.
Five participants (etanercept + methotrexate: 3, DMARD + methotrexate: 2) were randomized but did not receive study treatment. These participants were either randomized in error or withdrew consent before receiving the first dose. Phase 1 DMARD therapy was either hydroxychloroquine (HCQ) or sulfsalazine (SSZ), as selected by the investigator.
Participant milestones
| Measure |
Etanercept + Methotrexate
Phase 1: Etanercept 50 mg injection subcutaneously (s.c.) once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Phase 1
STARTED
|
281
|
143
|
|
Phase 1
COMPLETED
|
269
|
129
|
|
Phase 1
NOT COMPLETED
|
12
|
14
|
|
Phase 2 Year 1
STARTED
|
260
|
126
|
|
Phase 2 Year 1
COMPLETED
|
242
|
120
|
|
Phase 2 Year 1
NOT COMPLETED
|
18
|
6
|
|
Phase 2 Year 2
STARTED
|
241
|
120
|
|
Phase 2 Year 2
COMPLETED
|
218
|
113
|
|
Phase 2 Year 2
NOT COMPLETED
|
23
|
7
|
Reasons for withdrawal
| Measure |
Etanercept + Methotrexate
Phase 1: Etanercept 50 mg injection subcutaneously (s.c.) once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Phase 1
Adverse Event
|
5
|
4
|
|
Phase 1
Discontinuation of study by sponsor
|
2
|
1
|
|
Phase 1
Failed to return
|
0
|
1
|
|
Phase 1
Lost to Follow-up
|
1
|
1
|
|
Phase 1
Unspecified Reason
|
1
|
1
|
|
Phase 1
Protocol Violation
|
1
|
1
|
|
Phase 1
Withdrawal by Subject
|
2
|
4
|
|
Phase 1
Lack of Efficacy
|
0
|
1
|
|
Phase 2 Year 1
Adverse Event
|
7
|
2
|
|
Phase 2 Year 1
Death
|
1
|
0
|
|
Phase 2 Year 1
Failed to Return
|
1
|
1
|
|
Phase 2 Year 1
Lost to Follow-up
|
1
|
0
|
|
Phase 2 Year 1
Unspecified Reason
|
3
|
0
|
|
Phase 2 Year 1
Protocol Violation
|
4
|
1
|
|
Phase 2 Year 1
Subject Request
|
1
|
2
|
|
Phase 2 Year 2
Adverse Event
|
12
|
2
|
|
Phase 2 Year 2
Death
|
2
|
0
|
|
Phase 2 Year 2
Failed to return
|
3
|
0
|
|
Phase 2 Year 2
Lost to Follow-up
|
1
|
3
|
|
Phase 2 Year 2
Unspecified Reason
|
1
|
0
|
|
Phase 2 Year 2
Protocol Violation
|
1
|
1
|
|
Phase 2 Year 2
Subject Request
|
1
|
1
|
|
Phase 2 Year 2
Unsatisfactory Response - Efficacy
|
2
|
0
|
Baseline Characteristics
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
Baseline characteristics by cohort
| Measure |
Etanercept + Methotrexate
n=281 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=143 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
Total
n=424 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
48.4 years
STANDARD_DEVIATION 11.99 • n=99 Participants
|
48.7 years
STANDARD_DEVIATION 11.40 • n=107 Participants
|
48.5 years
STANDARD_DEVIATION 11.78 • n=206 Participants
|
|
Sex: Female, Male
Female
|
248 Participants
n=99 Participants
|
129 Participants
n=107 Participants
|
377 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
33 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
47 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Week 24Population: Modified intent-to-treat (mITT) population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. Last Observation carried forward (LOCF) method was used.
ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of the Health Assessment Questionnaire; HAQ); and C-Reactive Protein (CRP).
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response at Week 24
|
62.01 Percentage of participants
|
23.24 Percentage of participants
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
HAQ: self-reported, valid assessment of functional disability in rheumatoid arthritis. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. HAQ score range: 0-3: without any difficulty: 0, with some difficulty: 1, with much difficulty: 2, unable to do: 3. HAQ total scores expressed as overall mean score with range 0-3: 0-0.25: normal functioning; 0.25-0.5: mild functional limitation; 0.5-1: moderate functional limitation; more than 1: significant functional limitation.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=141 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in HAQ Score at Week 24
Baseline
|
1.55 Units on a scale
Standard Error 0.05
|
1.51 Units on a scale
Standard Error 0.07
|
|
Change From Baseline in HAQ Score at Week 24
Change at Week 24
|
-0.85 Units on a scale
Standard Error 0.04
|
-0.51 Units on a scale
Standard Error 0.06
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=278 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=141 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24
Baseline, Vitality domain
|
12.46 Units on a scale
Standard Error 0.28
|
12.39 Units on a scale
Standard Error 0.36
|
|
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24
Baseline, Mental component
|
40.50 Units on a scale
Standard Error 0.78
|
40.41 Units on a scale
Standard Error 1.00
|
|
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24
Baseline, Physical component
|
30.42 Units on a scale
Standard Error 0.50
|
30.18 Units on a scale
Standard Error 0.64
|
|
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24
Change at Week 24, Vitality domain
|
3.79 Units on a scale
Standard Error 0.27
|
2.36 Units on a scale
Standard Error 0.35
|
|
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24
Change at Week 24, Mental component
|
7.33 Units on a scale
Standard Error 0.73
|
3.32 Units on a scale
Standard Error 0.95
|
|
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24
Change at Week 24, Physical component
|
12.44 Units on a scale
Standard Error 0.65
|
7.36 Units on a scale
Standard Error 0.84
|
SECONDARY outcome
Timeframe: Baseline and Week 24Population: Radiographic intent-to-treat (xITT) population included all participants who took at least 1 dose of study drug and had evaluable radiographic data at Baseline and Week 24.
mTSS: sum of erosion and joint space narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Each x-ray visit included 4 films, each of which were read by 2 readers. The mTSS was calculated by the images scored for erosions and JSN. An increase in mTSS from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=247 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=119 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdH mTSS), Annualized, at Week 24
Baseline
|
31.19 units on a scale
Standard Error 4.06
|
46.35 units on a scale
Standard Error 5.35
|
|
Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdH mTSS), Annualized, at Week 24
Week 24
|
0.40 units on a scale
Standard Error 0.36
|
1.37 units on a scale
Standard Error 0.47
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28 calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour; mm/hour) and the participant's general health using a 100 mm-visual analog scale (VAS). DAS28\<3.2 indicates low disease activity and DAS28\<2.6 remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
-1.50 units on a scale
Standard Error 0.07
|
-0.67 units on a scale
Standard Error 0.09
|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
-2.15 units on a scale
Standard Error 0.08
|
-1.27 units on a scale
Standard Error 0.10
|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-2.59 units on a scale
Standard Error 0.09
|
-1.54 units on a scale
Standard Error 0.11
|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-2.82 units on a scale
Standard Error 0.09
|
-1.83 units on a scale
Standard Error 0.12
|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-3.01 units on a scale
Standard Error 0.09
|
-1.84 units on a scale
Standard Error 0.12
|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-3.15 units on a scale
Standard Error 0.09
|
-1.84 units on a scale
Standard Error 0.12
|
|
Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-3.20 units on a scale
Standard Error 0.09
|
-1.70 units on a scale
Standard Error 0.12
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28 calculated from the number of swollen joints and painful joints using the 28 joints count, the ESR (mm/hour) and the participant's general health using a 100 mm-VAS. DAS28\<3.2 indicates low disease activity and DAS28\<2.6 remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-3.39 units on a scale
Standard Deviation 1.34
|
-3.08 units on a scale
Standard Deviation 1.29
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-3.42 units on a scale
Standard Deviation 1.32
|
-3.33 units on a scale
Standard Deviation 1.18
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-3.41 units on a scale
Standard Deviation 1.31
|
-3.42 units on a scale
Standard Deviation 1.16
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-3.38 units on a scale
Standard Deviation 1.33
|
-3.36 units on a scale
Standard Deviation 1.27
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-3.53 units on a scale
Standard Deviation 1.34
|
-3.47 units on a scale
Standard Deviation 1.34
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-3.43 units on a scale
Standard Deviation 1.26
|
-3.47 units on a scale
Standard Deviation 1.29
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-3.47 units on a scale
Standard Deviation 1.31
|
-3.28 units on a scale
Standard Deviation 1.37
|
|
Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-3.41 units on a scale
Standard Deviation 1.40
|
-3.51 units on a scale
Standard Deviation 1.29
|
SECONDARY outcome
Timeframe: Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used. One participant was randomized to etanercept but received SSZ in Phase 1.
The investigators were allowed to alter each participant's therapy at the beginning of Phase 2. Continuations, discontinuations and additions made to Phase 1 treatment regimen were summarized.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Summary of Changes in Therapy at the Beginning of Phase 2
Discontinued HCQ
|
NA participants
Participants did not receive HCQ during Phase 1.
|
35 participants
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
No change: Etanercept
|
259 participants
|
NA participants
Participants did not receive etanercept during Phase 1.
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
No change: HCQ
|
NA participants
Participants did not receive HCQ during Phase 1.
|
29 participants
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
No change: Methotrexate
|
260 participants
|
126 participants
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
No change: SSZ
|
NA participants
Participants did not receive SSZ during Phase 1.
|
11 participants
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
Added Etanercept
|
1 participants
|
105 participants
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
Added HCQ
|
8 participants
|
NA participants
Participants already received HCQ during Phase 1.
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
Added SSZ
|
3 participants
|
NA participants
Participants already received SSZ during Phase 1.
|
|
Summary of Changes in Therapy at the Beginning of Phase 2
Discontinued SSZ
|
1 participants
|
51 participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and CRP.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 2 (N: 278, 140)
|
15.83 percentage of participants
|
2.86 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 4 (N: 279, 142)
|
31.54 percentage of participants
|
8.45 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 8 (N: 279, 142)
|
42.29 percentage of participants
|
16.90 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 12 (N: 279, 142)
|
52.33 percentage of participants
|
21.13 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 16 (N: 279, 142)
|
56.27 percentage of participants
|
24.65 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 20 (N: 279, 142)
|
59.14 percentage of participants
|
27.46 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20
Week 24 (N: 279, 142)
|
62.01 percentage of participants
|
23.24 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and ESR.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
67.31 percentage of participants
|
53.17 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
65.77 percentage of participants
|
60.32 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
68.46 percentage of participants
|
62.70 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
67.31 percentage of participants
|
58.73 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
73.44 percentage of participants
|
60.83 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
73.44 percentage of participants
|
61.67 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
72.61 percentage of participants
|
59.17 percentage of participants
|
|
Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
70.54 percentage of participants
|
65.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
ACR20 response: greater than or equal to 20 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 20 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and CRP.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
47.84 percentage of participants
|
19.29 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
63.80 percentage of participants
|
34.51 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
73.84 percentage of participants
|
49.30 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
79.57 percentage of participants
|
54.93 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
84.23 percentage of participants
|
57.75 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
84.59 percentage of participants
|
58.45 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
83.15 percentage of participants
|
50.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
ACR20 response: greater than or equal to 20 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 20 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and ESR.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
89.23 percentage of participants
|
87.30 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
90.87 percentage of participants
|
89.17 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
91.70 percentage of participants
|
90.83 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
90.04 percentage of participants
|
83.33 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
89.21 percentage of participants
|
89.17 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
86.92 percentage of participants
|
80.95 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
90.00 percentage of participants
|
86.51 percentage of participants
|
|
Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
88.85 percentage of participants
|
91.27 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
ACR70 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 70 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and CRP.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
3.60 percentage of participants
|
0.71 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
7.17 percentage of participants
|
2.11 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
16.13 percentage of participants
|
3.52 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
20.07 percentage of participants
|
4.23 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
27.60 percentage of participants
|
9.15 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
30.11 percentage of participants
|
10.56 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
34.77 percentage of participants
|
11.27 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
ACR70 response: greater than or equal to 70 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 70 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and ESR.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
40.38 percentage of participants
|
30.16 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
45.00 percentage of participants
|
32.54 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
39.62 percentage of participants
|
34.13 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
41.92 percentage of participants
|
34.13 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
53.11 percentage of participants
|
38.33 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
48.96 percentage of participants
|
36.67 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
48.55 percentage of participants
|
35.00 percentage of participants
|
|
Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
48.96 percentage of participants
|
40.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS calculated from number of painful joints using the ritchie articular index (RAI), number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS≤2.4 indicates low disease activity and DAS\<1.6 remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 274, 139)
|
-1.42 units on a scale
Standard Error 0.07
|
-0.65 units on a scale
Standard Error 0.09
|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 277, 142)
|
-2.07 units on a scale
Standard Error 0.07
|
-1.29 units on a scale
Standard Error 0.09
|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 278, 142)
|
-2.45 units on a scale
Standard Error 0.07
|
-1.55 units on a scale
Standard Error 0.10
|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 278, 142)
|
-2.67 units on a scale
Standard Error 0.08
|
-1.79 units on a scale
Standard Error 0.10
|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 278, 142)
|
-2.82 units on a scale
Standard Error 0.08
|
-1.86 units on a scale
Standard Error 0.10
|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 278, 142)
|
-2.95 units on a scale
Standard Error 0.08
|
-1.85 units on a scale
Standard Error 0.10
|
|
Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 278, 142)
|
-2.97 units on a scale
Standard Error 0.08
|
-1.72 units on a scale
Standard Error 0.10
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS≤2.4 indicates low disease activity and DAS\<1.6 remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 259, 126)
|
-3.17 units on a scale
Standard Deviation 1.19
|
-3.26 units on a scale
Standard Deviation 1.19
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 259, 126)
|
-3.18 units on a scale
Standard Deviation 1.28
|
-3.24 units on a scale
Standard Deviation 1.23
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 239, 120)
|
-3.29 units on a scale
Standard Deviation 1.27
|
-3.26 units on a scale
Standard Deviation 1.38
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 239, 120)
|
-3.24 units on a scale
Standard Deviation 1.23
|
-3.31 units on a scale
Standard Deviation 1.31
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 239, 120)
|
-3.28 units on a scale
Standard Deviation 1.22
|
-3.18 units on a scale
Standard Deviation 1.41
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 259, 126)
|
-3.13 units on a scale
Standard Deviation 1.28
|
-2.94 units on a scale
Standard Deviation 1.25
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 259, 126)
|
-3.21 units on a scale
Standard Deviation 1.24
|
-3.19 units on a scale
Standard Deviation 1.12
|
|
Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 239, 120)
|
-3.23 units on a scale
Standard Deviation 1.32
|
-3.35 units on a scale
Standard Deviation 1.38
|
SECONDARY outcome
Timeframe: Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS\<2.4: low disease activity, DAS\<1.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=278 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS<2.4 (Low Disease Activity) Response at Week 24
|
61.51 percentage of participants
|
20.42 percentage of participants
|
SECONDARY outcome
Timeframe: Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS\<2.4: low disease activity, DAS\<1.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=278 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS<1.6 (Remission) Response at Week 24
|
28.78 percentage of participants
|
4.93 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS\<2.4: low disease activity, DAS\<1.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 274, 139)
|
79.93 percentage of participants
|
53.24 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 277, 142)
|
90.97 percentage of participants
|
66.90 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 278, 142)
|
95.68 percentage of participants
|
78.87 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 278, 142)
|
95.32 percentage of participants
|
81.69 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 278, 142)
|
96.76 percentage of participants
|
83.10 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 278, 142)
|
97.12 percentage of participants
|
83.10 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 278, 142)
|
96.04 percentage of participants
|
76.06 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS\<2.4: low disease activity, DAS\<1.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 259, 126)
|
98.46 percentage of participants
|
98.41 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 259, 126)
|
96.91 percentage of participants
|
99.21 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 259, 126)
|
96.53 percentage of participants
|
98.41 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 239, 120)
|
97.49 percentage of participants
|
98.33 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 239, 120)
|
98.74 percentage of participants
|
98.33 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 239, 120)
|
98.33 percentage of participants
|
96.67 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 239, 120)
|
97.07 percentage of participants
|
99.17 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 259, 126)
|
98.07 percentage of participants
|
96.83 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS\<2.4: low disease activity, DAS\<1.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 274, 139)
|
57.66 percentage of participants
|
30.22 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 277, 142)
|
78.34 percentage of participants
|
45.07 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 278, 142)
|
84.89 percentage of participants
|
58.45 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 278, 142)
|
87.77 percentage of participants
|
64.79 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 278, 142)
|
92.09 percentage of participants
|
67.61 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 278, 142)
|
91.73 percentage of participants
|
66.90 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 278, 142)
|
91.01 percentage of participants
|
60.56 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS\<2.4: low disease activity, DAS\<1.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 259, 126)
|
95.37 percentage of participants
|
89.68 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 259, 126)
|
96.53 percentage of participants
|
96.03 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 259, 126)
|
95.75 percentage of participants
|
95.24 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 259, 126)
|
94.21 percentage of participants
|
96.03 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 239, 120)
|
94.56 percentage of participants
|
94.17 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 239, 120)
|
95.40 percentage of participants
|
97.50 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 239, 120)
|
97.49 percentage of participants
|
94.17 percentage of participants
|
|
Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 239, 120)
|
94.14 percentage of participants
|
95.83 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS-based EULAR response was defined as: * DAS-value ≤3.7 and DAS-improvement from Baseline \>0.6 * DAS-value \>3.7 and DAS-improvement from Baseline \>1.2
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 274, 139)
|
66.42 percentage of participants
|
35.97 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 277, 142)
|
84.12 percentage of participants
|
52.11 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 278, 142)
|
89.93 percentage of participants
|
64.08 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 278, 142)
|
91.01 percentage of participants
|
69.72 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 278, 142)
|
93.88 percentage of participants
|
72.54 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 278, 142)
|
94.6 percentage of participants
|
73.94 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 278, 142)
|
92.45 percentage of participants
|
65.49 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS-based EULAR response was defined as: * DAS-value ≤3.7 and DAS-improvement from Baseline \>0.6 * DAS-value \>3.7 and DAS-improvement from Baseline \>1.2
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 259, 126)
|
97.3 percentage of participants
|
93.65 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 259, 126)
|
97.3 percentage of participants
|
97.62 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 259, 126)
|
96.53 percentage of participants
|
98.41 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 259, 126)
|
95.37 percentage of participants
|
97.62 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 239, 120)
|
97.07 percentage of participants
|
97.50 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 239, 120)
|
97.49 percentage of participants
|
97.50 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 239, 120)
|
98.33 percentage of participants
|
96.67 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 239, 120)
|
96.23 percentage of participants
|
98.33 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS-based EULAR response was defined as: DAS-value ≤2.4 and DAS-improvement from Baseline \>1.2.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 277, 142)
|
24.55 percentage of participants
|
7.75 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 278, 142)
|
39.21 percentage of participants
|
15.49 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 278, 142)
|
48.2 percentage of participants
|
22.54 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 278, 142)
|
56.12 percentage of participants
|
22.54 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 278, 142)
|
58.99 percentage of participants
|
24.65 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 278, 142)
|
61.15 percentage of participants
|
20.42 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 274, 139)
|
8.39 percentage of participants
|
2.88 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS-based EULAR response was defined as: DAS-value ≤2.4 and DAS-improvement from Baseline \>1.2.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 259, 126)
|
73.36 percentage of participants
|
56.35 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 259, 126)
|
72.2 percentage of participants
|
69.05 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 259, 126)
|
72.97 percentage of participants
|
70.63 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 259, 126)
|
73.75 percentage of participants
|
64.29 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 239, 120)
|
76.57 percentage of participants
|
68.33 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 239, 120)
|
77.41 percentage of participants
|
70.83 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 239, 120)
|
76.57 percentage of participants
|
66.67 percentage of participants
|
|
Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 239, 120)
|
75.73 percentage of participants
|
70.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS28-based EULAR response was defined as: * DAS28-value ≤5.1 and DAS28-improvement from Baseline \>0.6 * DAS28-value \>5.1 and DAS28-improvement from Baseline \>1.2
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
64 percentage of participants
|
29.5 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
81.29 percentage of participants
|
48.59 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
88.89 percentage of participants
|
60.56 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
91.4 percentage of participants
|
64.79 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
93.91 percentage of participants
|
68.31 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
94.62 percentage of participants
|
67.61 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
91.76 percentage of participants
|
64.79 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS28-based EULAR response was defined as: * DAS28-value ≤5.1 and DAS28-improvement from Baseline \>0.6 * DAS28-value \>5.1 and DAS28-improvement from Baseline \>1.2
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
95.77 percentage of participants
|
93.65 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
96.15 percentage of participants
|
95.24 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
96.15 percentage of participants
|
96.83 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
95 percentage of participants
|
96.83 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
95.85 percentage of participants
|
96.67 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
95.02 percentage of participants
|
96.67 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
95.44 percentage of participants
|
93.33 percentage of participants
|
|
Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
92.95 percentage of participants
|
97.50 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS28-based EULAR response was defined as: DAS28-value ≤3.2 and DAS28-improvement from Baseline \>1.2.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
5.09 percentage of participants
|
0.72 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
10.79 percentage of participants
|
4.93 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
22.22 percentage of participants
|
9.15 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
30.11 percentage of participants
|
12.68 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
38.35 percentage of participants
|
16.9 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
43.01 percentage of participants
|
15.49 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
46.95 percentage of participants
|
11.97 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS28-based EULAR response was defined as: DAS28-value ≤3.2 and DAS28-improvement from Baseline \>1.2.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
53.08 percentage of participants
|
37.3 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
54.62 percentage of participants
|
45.24 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
55.38 percentage of participants
|
50.79 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
56.92 percentage of participants
|
44.44 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
60.58 percentage of participants
|
50.83 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
56.43 percentage of participants
|
50.00 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
56.85 percentage of participants
|
45.83 percentage of participants
|
|
Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
57.68 percentage of participants
|
55.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
1.45 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
4.32 percentage of participants
|
2.11 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
10.04 percentage of participants
|
4.23 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
14.7 percentage of participants
|
5.63 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
20.43 percentage of participants
|
5.63 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
28.67 percentage of participants
|
6.34 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
25.09 percentage of participants
|
3.52 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
33.85 percentage of participants
|
22.22 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
36.54 percentage of participants
|
26.19 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
38.46 percentage of participants
|
26.19 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
33.46 percentage of participants
|
23.02 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
45.64 percentage of participants
|
34.17 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
36.93 percentage of participants
|
36.67 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
39.42 percentage of participants
|
30.00 percentage of participants
|
|
Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
39.83 percentage of participants
|
33.33 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
5.09 percentage of participants
|
0.72 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
10.79 percentage of participants
|
4.93 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
22.22 percentage of participants
|
9.15 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
30.11 percentage of participants
|
12.68 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
38.35 percentage of participants
|
16.9 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
43.01 percentage of participants
|
15.49 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
46.95 percentage of participants
|
11.97 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
53.08 percentage of participants
|
37.3 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
54.62 percentage of participants
|
45.24 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
55.38 percentage of participants
|
50.79 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
56.92 percentage of participants
|
44.44 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
60.58 percentage of participants
|
50.83 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
56.43 percentage of participants
|
50.00 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
56.85 percentage of participants
|
45.83 percentage of participants
|
|
Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
57.68 percentage of participants
|
55.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
80.36 percentage of participants
|
47.48 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
89.93 percentage of participants
|
69.01 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
93.91 percentage of participants
|
74.65 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
95.34 percentage of participants
|
79.58 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
96.06 percentage of participants
|
78.87 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
96.77 percentage of participants
|
78.17 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
95.70 percentage of participants
|
73.94 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
97.31 percentage of participants
|
96.03 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
98.46 percentage of participants
|
97.62 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
96.92 percentage of participants
|
99.21 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
96.54 percentage of participants
|
99.21 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
96.27 percentage of participants
|
99.17 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
97.10 percentage of participants
|
97.50 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
97.10 percentage of participants
|
95.00 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
96.68 percentage of participants
|
98.33 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
57.09 percentage of participants
|
26.62 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
78.78 percentage of participants
|
44.37 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
87.46 percentage of participants
|
58.45 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
89.96 percentage of participants
|
62.68 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
92.47 percentage of participants
|
68.31 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
93.55 percentage of participants
|
64.79 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
90.32 percentage of participants
|
61.97 percentage of participants
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant's general health using a 100 mm-VAS. DAS28\<3.2: low disease activity, DAS28\<2.6: remission.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
95.00 percentage of participants
|
91.27 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
95.38 percentage of participants
|
94.44 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
95.77 percentage of participants
|
96.03 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
94.62 percentage of participants
|
92.86 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
94.61 percentage of participants
|
95.00 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
94.61 percentage of participants
|
94.17 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
95.02 percentage of participants
|
92.50 percentage of participants
|
|
Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
92.95 percentage of participants
|
95.00 percentage of participants
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
Painful joint count is a physical assessment of the ACR-specified 68 joint set for tenderness/pain. Each joint is rated as either painful or not painful with the total number of painful joints reported as the score. Score range is from 0-68 with lower scores indicating the better outcome.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
-10.28 units on a scale
Standard Error 0.71
|
-5.65 units on a scale
Standard Error 0.91
|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-15.01 units on a scale
Standard Error 0.68
|
-9.99 units on a scale
Standard Error 0.87
|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-17.47 units on a scale
Standard Error 0.63
|
-12.27 units on a scale
Standard Error 0.80
|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-18.70 units on a scale
Standard Error 0.63
|
-13.82 units on a scale
Standard Error 0.81
|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-19.44 units on a scale
Standard Error 0.66
|
-14.00 units on a scale
Standard Error 0.85
|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-20.06 units on a scale
Standard Error 0.62
|
-13.85 units on a scale
Standard Error 0.79
|
|
Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-19.77 units on a scale
Standard Error 0.64
|
-12.83 units on a scale
Standard Error 0.82
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
Painful joint count is a physical assessment of the ACR-specified 68 joint set for tenderness/pain. Each joint is rated as either painful or not painful with the total number of painful joints reported as the score. Score range is from 0-68 with lower scores indicating the better outcome.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-21.14 units on a scale
Standard Deviation 11.76
|
-21.43 units on a scale
Standard Deviation 13.65
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-21.47 units on a scale
Standard Deviation 11.75
|
-22.50 units on a scale
Standard Deviation 12.75
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-21.43 units on a scale
Standard Deviation 11.91
|
-23.72 units on a scale
Standard Deviation 12.74
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-21.10 units on a scale
Standard Deviation 12.42
|
-22.90 units on a scale
Standard Deviation 12.78
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-21.55 units on a scale
Standard Deviation 11.93
|
-23.02 units on a scale
Standard Deviation 12.87
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-21.67 units on a scale
Standard Deviation 11.91
|
-23.51 units on a scale
Standard Deviation 13.13
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-21.74 units on a scale
Standard Deviation 11.82
|
-22.72 units on a scale
Standard Deviation 12.94
|
|
Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-21.44 units on a scale
Standard Deviation 12.13
|
-23.96 units on a scale
Standard Deviation 13.25
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
Swollen joint count is a physical assessment of the ACR-specified 66 joint set for swelling. Each joint is rated as either swollen or not swollen with the total number of swollen joints reported as the score. Score range is from 0-66 with lower scores indicating the better outcome.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
-7.11 units on a scale
Standard Error 0.56
|
-3.15 units on a scale
Standard Error 0.72
|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-10.69 units on a scale
Standard Error 0.49
|
-6.98 units on a scale
Standard Error 0.63
|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-12.96 units on a scale
Standard Error 0.46
|
-8.23 units on a scale
Standard Error 0.59
|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-14.07 units on a scale
Standard Error 0.43
|
-9.42 units on a scale
Standard Error 0.56
|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-14.57 units on a scale
Standard Error 0.40
|
-9.78 units on a scale
Standard Error 0.52
|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-15.21 units on a scale
Standard Error 0.40
|
-9.57 units on a scale
Standard Error 0.51
|
|
Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-15.07 units on a scale
Standard Error 0.42
|
-8.62 units on a scale
Standard Error 0.55
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
Swollen joint count is a physical assessment of the ACR-specified 66 joint set for swelling. Each joint is rated as either swollen or not swollen with the total number of swollen joints reported as the score. Score range is from 0-66 with lower scores indicating the better outcome.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-16.16 units on a scale
Standard Deviation 8.75
|
-16.01 units on a scale
Standard Deviation 10.30
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-16.54 units on a scale
Standard Deviation 8.74
|
-17.40 units on a scale
Standard Deviation 9.57
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-16.48 units on a scale
Standard Deviation 8.46
|
-18.02 units on a scale
Standard Deviation 10.27
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-16.57 units on a scale
Standard Deviation 9.02
|
-17.71 units on a scale
Standard Deviation 10.32
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-16.69 units on a scale
Standard Deviation 8.77
|
-18.03 units on a scale
Standard Deviation 10.64
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-16.93 units on a scale
Standard Deviation 8.60
|
-18.22 units on a scale
Standard Deviation 10.84
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-17.07 units on a scale
Standard Deviation 8.71
|
-17.76 units on a scale
Standard Deviation 11.71
|
|
Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-16.58 units on a scale
Standard Deviation 8.99
|
-18.45 units on a scale
Standard Deviation 11.17
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The participant's global disease activity was estimated over the preceding 2-3 days on a scale from 0 (no disease activity) to 10 (extreme disease activity) by the physician.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
-2.68 units on a scale
Standard Error 0.12
|
-1.38 units on a scale
Standard Error 0.15
|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-3.69 units on a scale
Standard Error 0.12
|
-2.21 units on a scale
Standard Error 0.16
|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-4.14 units on a scale
Standard Error 0.12
|
-2.63 units on a scale
Standard Error 0.15
|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-4.25 units on a scale
Standard Error 0.13
|
-2.67 units on a scale
Standard Error 0.17
|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-4.49 units on a scale
Standard Error 0.13
|
-2.84 units on a scale
Standard Error 0.16
|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-4.64 units on a scale
Standard Error 0.12
|
-2.85 units on a scale
Standard Error 0.16
|
|
Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-4.75 units on a scale
Standard Error 0.13
|
-2.44 units on a scale
Standard Error 0.17
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The participant's global disease activity was estimated over the preceding 2-3 days on a scale from 0 (no disease activity) to 10 (extreme disease activity) by the physician.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-5.03 units on a scale
Standard Deviation 1.96
|
-4.42 units on a scale
Standard Deviation 1.99
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-5.14 units on a scale
Standard Deviation 1.91
|
-4.79 units on a scale
Standard Deviation 2.09
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-5.08 units on a scale
Standard Deviation 1.97
|
-5.02 units on a scale
Standard Deviation 1.84
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-5.18 units on a scale
Standard Deviation 1.98
|
-4.97 units on a scale
Standard Deviation 1.82
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-5.25 units on a scale
Standard Deviation 2.01
|
-5.13 units on a scale
Standard Deviation 2.09
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-5.16 units on a scale
Standard Deviation 1.87
|
-5.18 units on a scale
Standard Deviation 1.92
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-5.26 units on a scale
Standard Deviation 1.86
|
-5.01 units on a scale
Standard Deviation 2.05
|
|
Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-5.22 units on a scale
Standard Deviation 2.08
|
-5.18 units on a scale
Standard Deviation 2.00
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The participant assessed overall arthritis activity on a scale from 0 (no disease activity) to 10 (extreme disease activity).
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 2 (N: 278, 140)
|
-2.14 units on a scale
Standard Error 0.14
|
-1.01 units on a scale
Standard Error 0.18
|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 4 (N: 279, 142)
|
-2.69 units on a scale
Standard Error 0.15
|
-1.54 units on a scale
Standard Error 0.19
|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 8 (N: 279, 142)
|
-3.13 units on a scale
Standard Error 0.16
|
-1.93 units on a scale
Standard Error 0.20
|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 12 (N: 279, 142)
|
-3.35 units on a scale
Standard Error 0.16
|
-2.20 units on a scale
Standard Error 0.21
|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 16 (N: 279, 142)
|
-3.55 units on a scale
Standard Error 0.16
|
-2.33 units on a scale
Standard Error 0.21
|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 20 (N: 279, 142)
|
-3.83 units on a scale
Standard Error 0.15
|
-2.34 units on a scale
Standard Error 0.20
|
|
Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Week 24 (N: 279, 142)
|
-3.87 units on a scale
Standard Error 0.16
|
-2.31 units on a scale
Standard Error 0.21
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The participant assessed overall arthritis activity on a scale from 0 (no disease activity) to 10 (extreme disease activity).
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-3.80 units on a scale
Standard Deviation 2.90
|
-3.27 units on a scale
Standard Deviation 3.16
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-3.85 units on a scale
Standard Deviation 2.82
|
-3.44 units on a scale
Standard Deviation 2.90
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-3.83 units on a scale
Standard Deviation 2.87
|
-3.72 units on a scale
Standard Deviation 3.07
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-3.88 units on a scale
Standard Deviation 2.96
|
-3.42 units on a scale
Standard Deviation 2.80
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-4.09 units on a scale
Standard Deviation 2.92
|
-3.91 units on a scale
Standard Deviation 2.93
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-4.14 units on a scale
Standard Deviation 2.60
|
-3.83 units on a scale
Standard Deviation 2.92
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-4.11 units on a scale
Standard Deviation 2.85
|
-3.71 units on a scale
Standard Deviation 3.11
|
|
Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-4.28 units on a scale
Standard Deviation 2.73
|
-3.82 units on a scale
Standard Deviation 2.80
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The duration of morning stiffness was determined over the preceding 2 days using a 2-question worksheet.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 276, 137)
|
-60.59 min
Standard Error 8.31
|
-11.17 min
Standard Error 10.71
|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 141)
|
-74.79 min
Standard Error 7.95
|
-35.63 min
Standard Error 10.21
|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 141)
|
-96.13 min
Standard Error 7.84
|
-58.55 min
Standard Error 10.06
|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 141)
|
-100.2 min
Standard Error 7.32
|
-64.29 min
Standard Error 9.39
|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 141)
|
-96.77 min
Standard Error 8.13
|
-55.90 min
Standard Error 10.44
|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 141)
|
-103.3 min
Standard Error 7.30
|
-58.21 min
Standard Error 9.37
|
|
Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 141)
|
-102.1 min
Standard Error 8.08
|
-53.66 min
Standard Error 10.37
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The duration of morning stiffness was determined over the preceding 2 days using a 2-question worksheet.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 125)
|
-105.39 min
Standard Deviation 189.12
|
-87.89 min
Standard Deviation 162.76
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 125)
|
-105.75 min
Standard Deviation 199.90
|
-97.61 min
Standard Deviation 164.68
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 125)
|
-104.18 min
Standard Deviation 201.17
|
-89.61 min
Standard Deviation 170.16
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 125)
|
-98.83 min
Standard Deviation 202.56
|
-91.53 min
Standard Deviation 181.67
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-125.07 min
Standard Deviation 262.93
|
-76.49 min
Standard Deviation 226.83
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-132.32 min
Standard Deviation 243.81
|
-84.53 min
Standard Deviation 205.70
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-130.55 min
Standard Deviation 267.87
|
-89.53 min
Standard Deviation 196.35
|
|
Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-118.79 min
Standard Deviation 294.73
|
-90.88 min
Standard Deviation 206.55
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The participants had to indicate on a 100 mm-VAS (0 mm: very well, 100 mm: extremely bad) in general how they rated their health over the preceding 2-3 weeks.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
-20.51 mm
Standard Error 1.43
|
-8.75 mm
Standard Error 1.82
|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-25.23 mm
Standard Error 1.49
|
-13.11 mm
Standard Error 1.90
|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-28.17 mm
Standard Error 1.60
|
-17.00 mm
Standard Error 2.04
|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-30.54 mm
Standard Error 1.57
|
-19.60 mm
Standard Error 2.00
|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-32.69 mm
Standard Error 1.66
|
-21.04 mm
Standard Error 2.11
|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-34.69 mm
Standard Error 1.50
|
-20.04 mm
Standard Error 1.91
|
|
Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-33.71 mm
Standard Error 1.58
|
-19.27 mm
Standard Error 2.01
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The participants had to indicate on a 100 mm-VAS (0 mm: very well, 100 mm: extremely bad) in general how they rated their health over the preceding 2-3 weeks.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-34.48 mm
Standard Deviation 29.60
|
-31.02 mm
Standard Deviation 29.91
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-33.47 mm
Standard Deviation 27.53
|
-31.51 mm
Standard Deviation 25.99
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-33.53 mm
Standard Deviation 28.05
|
-34.33 mm
Standard Deviation 27.40
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-33.25 mm
Standard Deviation 28.44
|
-33.11 mm
Standard Deviation 27.12
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-34.79 mm
Standard Deviation 29.13
|
-34.78 mm
Standard Deviation 26.96
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-34.84 mm
Standard Deviation 27.07
|
-35.30 mm
Standard Deviation 27.60
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-34.86 mm
Standard Deviation 27.41
|
-32.11 mm
Standard Deviation 27.75
|
|
Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-36.25 mm
Standard Deviation 27.09
|
-36.35 mm
Standard Deviation 27.57
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The participants had to indicate on a 100 mm-VAS (0 mm: no pain, 100 mm: pain as bad as it could be) the amount of pain they experienced over the preceding 2-3 days.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
-27.66 mm
Standard Error 1.48
|
-10.46 mm
Standard Error 1.90
|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-31.58 mm
Standard Error 1.60
|
-16.30 mm
Standard Error 2.04
|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-36.05 mm
Standard Error 1.60
|
-23.45 mm
Standard Error 2.05
|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-37.24 mm
Standard Error 1.65
|
-23.74 mm
Standard Error 2.11
|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-39.86 mm
Standard Error 1.62
|
-24.30 mm
Standard Error 2.07
|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-40.59 mm
Standard Error 1.57
|
-24.75 mm
Standard Error 2.01
|
|
Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-40.91 mm
Standard Error 1.62
|
-23.97 mm
Standard Error 2.08
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The participants had to indicate on a 100 mm-VAS (0 mm: no pain, 100 mm: pain as bad as it could be) the amount of pain they experienced over the preceding 2-3 days.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-41.66 mm
Standard Deviation 27.84
|
-36.89 mm
Standard Deviation 29.64
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-40.49 mm
Standard Deviation 27.84
|
-36.63 mm
Standard Deviation 27.71
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-39.98 mm
Standard Deviation 27.23
|
-39.36 mm
Standard Deviation 26.85
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-40.38 mm
Standard Deviation 28.94
|
-37.17 mm
Standard Deviation 27.12
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-42.37 mm
Standard Deviation 29.14
|
-38.55 mm
Standard Deviation 28.17
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-41.99 mm
Standard Deviation 27.73
|
-39.85 mm
Standard Deviation 27.69
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-42.27 mm
Standard Deviation 26.65
|
-36.92 mm
Standard Deviation 27.55
|
|
Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-41.95 mm
Standard Deviation 28.56
|
-40.57 mm
Standard Deviation 26.81
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The participants had to indicate on a 100 mm-VAS (0 mm: no fatigue, 100 mm: a great deal of fatigue) how much of a problem had fatigue or tiredness been for them in the preceding week.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 278, 140)
|
-18.64 mm
Standard Error 1.48
|
-6.29 mm
Standard Error 1.90
|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-21.54 mm
Standard Error 1.59
|
-10.44 mm
Standard Error 2.04
|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-26.66 mm
Standard Error 1.55
|
-16.04 mm
Standard Error 1.98
|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-27.40 mm
Standard Error 1.63
|
-16.45 mm
Standard Error 2.08
|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-29.10 mm
Standard Error 1.68
|
-16.87 mm
Standard Error 2.15
|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-30.74 mm
Standard Error 1.61
|
-18.95 mm
Standard Error 2.06
|
|
Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-29.57 mm
Standard Error 1.64
|
-17.26 mm
Standard Error 2.10
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The participants had to indicate on a 100 mm-VAS (0 mm: no fatigue, 100 mm: a great deal of fatigue) how much of a problem had fatigue or tiredness been for them in the preceding week.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-30.87 mm
Standard Deviation 30.83
|
-27.38 mm
Standard Deviation 29.51
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-30.76 mm
Standard Deviation 29.09
|
-23.69 mm
Standard Deviation 29.10
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-29.03 mm
Standard Deviation 31.59
|
-25.32 mm
Standard Deviation 30.94
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-28.95 mm
Standard Deviation 31.51
|
-28.74 mm
Standard Deviation 31.19
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-29.44 mm
Standard Deviation 31.48
|
-28.17 mm
Standard Deviation 28.16
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-30.75 mm
Standard Deviation 30.78
|
-28.38 mm
Standard Deviation 31.05
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-30.37 mm
Standard Deviation 31.42
|
-30.61 mm
Standard Deviation 30.08
|
|
Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-30.52 mm
Standard Deviation 31.26
|
-30.35 mm
Standard Deviation 30.65
|
SECONDARY outcome
Timeframe: Week 24Population: xITT population included all participants who took at least 1 dose of study drug and had evaluable radiographic data at Baseline and Week 24.
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Each x-ray visit included 4 films, each of which were read by 2 readers. The mTSS was calculated by the images scored for erosions and JSN. An increase in mTSS from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=247 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=119 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Joint Space Narrowing Score Using vdH mTSS at Week 24
|
-0.01 units on a scale
Standard Error 0.22
|
0.23 units on a scale
Standard Error 0.28
|
SECONDARY outcome
Timeframe: Week 24Population: xITT population included all participants who took at least 1 dose of study drug and had evaluable radiographic data at Baseline and Week 24.
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Each x-ray visit included 4 films, each of which were read by 2 readers. The mTSS was calculated by the images scored for erosions and JSN. An increase in mTSS from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=247 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=119 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Erosion Score Using vdH mTSS at Week 24
|
0.42 units on a scale
Standard Error 0.22
|
1.14 units on a scale
Standard Error 0.29
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hour. A higher rate is consistent with inflammation. ESR was performed at the investigative site using an ESR kit supplied by the centralized laboratory.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 275, 139)
|
-13.16 mm/hour
Standard Error 0.96
|
-4.35 mm/hour
Standard Error 1.24
|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 278, 142)
|
-17.31 mm/hour
Standard Error 0.99
|
-8.06 mm/hour
Standard Error 1.27
|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-18.68 mm/hour
Standard Error 1.03
|
-10.11 mm/hour
Standard Error 1.31
|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-19.74 mm/hour
Standard Error 1.11
|
-12.53 mm/hour
Standard Error 1.42
|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-20.48 mm/hour
Standard Error 1.07
|
-12.87 mm/hour
Standard Error 1.37
|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-20.56 mm/hour
Standard Error 1.12
|
-12.60 mm/hour
Standard Error 1.44
|
|
Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-20.72 mm/hour
Standard Error 1.16
|
-12.37 mm/hour
Standard Error 1.48
|
SECONDARY outcome
Timeframe: Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hour. A higher rate is consistent with inflammation. ESR was performed at the investigative site using an ESR kit supplied by the centralized laboratory.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 37 (N: 260, 126)
|
-19.56 mm/hour
Standard Deviation 18.40
|
-20.25 mm/hour
Standard Deviation 14.92
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 50 (N: 260, 126)
|
-18.48 mm/hour
Standard Deviation 19.62
|
-20.27 mm/hour
Standard Deviation 16.78
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 63 (N: 260, 126)
|
-18.26 mm/hour
Standard Deviation 18.56
|
-18.31 mm/hour
Standard Deviation 17.68
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 76 (N: 260, 126)
|
-17.78 mm/hour
Standard Deviation 18.74
|
-17.54 mm/hour
Standard Deviation 20.00
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 89 (N: 241, 120)
|
-18.23 mm/hour
Standard Deviation 19.04
|
-17.08 mm/hour
Standard Deviation 19.74
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 102 (N: 241, 120)
|
-15.20 mm/hour
Standard Deviation 20.32
|
-16.63 mm/hour
Standard Deviation 19.00
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 115 (N: 241, 120)
|
-15.65 mm/hour
Standard Deviation 19.83
|
-15.30 mm/hour
Standard Deviation 21.70
|
|
Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128
Week 128 (N: 241, 120)
|
-13.75 mm/hour
Standard Deviation 22.36
|
-15.48 mm/hour
Standard Deviation 20.59
|
SECONDARY outcome
Timeframe: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. CRP was analysed at a central laboratory.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 24 (N: 279, 142)
|
-12.31 mg / dL
Standard Error 1.18
|
-7.06 mg / dL
Standard Error 1.51
|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 2 (N: 277, 139)
|
-13.39 mg / dL
Standard Error 1.30
|
-0.62 mg / dL
Standard Error 1.66
|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 4 (N: 279, 142)
|
-11.88 mg / dL
Standard Error 1.28
|
-3.15 mg / dL
Standard Error 1.64
|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 8 (N: 279, 142)
|
-11.81 mg / dL
Standard Error 1.36
|
-4.52 mg / dL
Standard Error 1.74
|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 12 (N: 279, 142)
|
-12.33 mg / dL
Standard Error 1.34
|
-5.80 mg / dL
Standard Error 1.72
|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 16 (N: 279, 142)
|
-12.98 mg / dL
Standard Error 1.31
|
-5.81 mg / dL
Standard Error 1.67
|
|
Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Week 20 (N: 279, 142)
|
-12.32 mg / dL
Standard Error 1.18
|
-4.39 mg / dL
Standard Error 1.52
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
3.43 units on a scale
Standard Error 0.26
|
2.00 units on a scale
Standard Error 0.33
|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
3.90 units on a scale
Standard Error 0.26
|
2.37 units on a scale
Standard Error 0.34
|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
3.79 units on a scale
Standard Error 0.27
|
2.36 units on a scale
Standard Error 0.35
|
SECONDARY outcome
Timeframe: Week 50, Week 76, Week 102, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 50, Week 76, Week 102, and Week 128
Week 50 (N: 259, 126)
|
4.08 units on a scale
Standard Deviation 4.72
|
3.56 units on a scale
Standard Deviation 4.04
|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 50, Week 76, Week 102, and Week 128
Week 76 (N: 259, 126)
|
3.71 units on a scale
Standard Deviation 4.83
|
3.49 units on a scale
Standard Deviation 4.16
|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 50, Week 76, Week 102, and Week 128
Week 102 (N: 241, 120)
|
4.00 units on a scale
Standard Deviation 4.55
|
3.60 units on a scale
Standard Deviation 4.64
|
|
Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 50, Week 76, Week 102, and Week 128
Week 128 (N: 241, 120)
|
3.89 units on a scale
Standard Deviation 4.95
|
3.62 units on a scale
Standard Deviation 4.28
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
6.85 units on a scale
Standard Error 0.65
|
2.98 units on a scale
Standard Error 0.84
|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
6.70 units on a scale
Standard Error 0.68
|
4.51 units on a scale
Standard Error 0.87
|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
7.33 units on a scale
Standard Error 0.73
|
3.32 units on a scale
Standard Error 0.95
|
SECONDARY outcome
Timeframe: Week 50, Week 76, Week 102, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 50, Week 76, Week 102, and Week 128
Week 50 (N: 259, 126)
|
8.28 units on a scale
Standard Deviation 11.62
|
5.61 units on a scale
Standard Deviation 9.95
|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 50, Week 76, Week 102, and Week 128
Week 76 (N: 259, 126)
|
7.39 units on a scale
Standard Deviation 12.71
|
6.61 units on a scale
Standard Deviation 10.66
|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 50, Week 76, Week 102, and Week 128
Week 102 (N: 241, 120)
|
7.19 units on a scale
Standard Deviation 12.49
|
6.05 units on a scale
Standard Deviation 11.61
|
|
Change From Baseline in SF-36 Health Survey Mental Component Score at Week 50, Week 76, Week 102, and Week 128
Week 128 (N: 241, 120)
|
7.32 units on a scale
Standard Deviation 12.86
|
6.42 units on a scale
Standard Deviation 11.48
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
10.08 units on a scale
Standard Error 0.60
|
7.04 units on a scale
Standard Error 0.78
|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
12.26 units on a scale
Standard Error 0.63
|
7.98 units on a scale
Standard Error 0.82
|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
12.44 units on a scale
Standard Error 0.65
|
7.36 units on a scale
Standard Error 0.84
|
SECONDARY outcome
Timeframe: Week 50, Week 76, Week 102, and Week 128Population: mITT population (LOCF) was used. Phase 2 Year 1 (week 37-week 76)-sample size (Etanercept + Methotrexate, DMARD + Methotrexate: 260, 126) is different from Phase 2 Year 2 (week 89-week 128)-sample size (241, 120).
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=260 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=126 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 50, Week 76, Week 102, and Week 128
Week 50 (N: 259, 126)
|
13.07 units on a scale
Standard Deviation 10.19
|
12.32 units on a scale
Standard Deviation 9.59
|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 50, Week 76, Week 102, and Week 128
Week 76 (N: 259, 126)
|
12.84 units on a scale
Standard Deviation 10.77
|
11.29 units on a scale
Standard Deviation 10.37
|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 50, Week 76, Week 102, and Week 128
Week 102 (N: 241, 120)
|
13.77 units on a scale
Standard Deviation 10.17
|
12.28 units on a scale
Standard Deviation 9.84
|
|
Change From Baseline in SF-36 Health Survey Physical Component Score at Week 50, Week 76, Week 102, and Week 128
Week 128 (N: 241, 120)
|
13.47 units on a scale
Standard Deviation 10.64
|
12.10 units on a scale
Standard Deviation 9.68
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Bodily Pain Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
2.93 units on a scale
Standard Error 0.15
|
1.84 units on a scale
Standard Error 0.19
|
|
Change From Baseline in SF-36 Health Survey Bodily Pain Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
3.24 units on a scale
Standard Error 0.15
|
2.24 units on a scale
Standard Error 0.20
|
|
Change From Baseline in SF-36 Health Survey Bodily Pain Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
3.39 units on a scale
Standard Error 0.16
|
2.00 units on a scale
Standard Error 0.21
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Role Limitations Due to Emotional Problems Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
0.87 units on a scale
Standard Error 0.09
|
0.51 units on a scale
Standard Error 0.11
|
|
Change From Baseline in SF-36 Health Survey Role Limitations Due to Emotional Problems Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
0.89 units on a scale
Standard Error 0.09
|
0.66 units on a scale
Standard Error 0.12
|
|
Change From Baseline in SF-36 Health Survey Role Limitations Due to Emotional Problems Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
1.04 units on a scale
Standard Error 0.09
|
0.46 units on a scale
Standard Error 0.11
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey General Health Perceptions Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
3.22 units on a scale
Standard Error 0.25
|
2.25 units on a scale
Standard Error 0.32
|
|
Change From Baseline in SF-36 Health Survey General Health Perceptions Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
3.62 units on a scale
Standard Error 0.25
|
2.56 units on a scale
Standard Error 0.32
|
|
Change From Baseline in SF-36 Health Survey General Health Perceptions Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
3.95 units on a scale
Standard Error 0.26
|
2.14 units on a scale
Standard Error 0.34
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Mental Health Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
3.21 units on a scale
Standard Error 0.30
|
1.25 units on a scale
Standard Error 0.38
|
|
Change From Baseline in SF-36 Health Survey Mental Health Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
3.62 units on a scale
Standard Error 0.30
|
2.21 units on a scale
Standard Error 0.39
|
|
Change From Baseline in SF-36 Health Survey Mental Health Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
3.59 units on a scale
Standard Error 0.33
|
1.81 units on a scale
Standard Error 0.42
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Physical Functioning Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
3.97 units on a scale
Standard Error 0.30
|
2.63 units on a scale
Standard Error 0.39
|
|
Change From Baseline in SF-36 Health Survey Physical Functioning Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
4.95 units on a scale
Standard Error 0.32
|
3.08 units on a scale
Standard Error 0.41
|
|
Change From Baseline in SF-36 Health Survey Physical Functioning Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
5.06 units on a scale
Standard Error 0.33
|
2.86 units on a scale
Standard Error 0.42
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Role Limitations Due to Physical Health Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
1.36 units on a scale
Standard Error 0.12
|
0.88 units on a scale
Standard Error 0.15
|
|
Change From Baseline in SF-36 Health Survey Role Limitations Due to Physical Health Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
1.67 units on a scale
Standard Error 0.12
|
1.08 units on a scale
Standard Error 0.15
|
|
Change From Baseline in SF-36 Health Survey Role Limitations Due to Physical Health Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
1.65 units on a scale
Standard Error 0.12
|
0.90 units on a scale
Standard Error 0.15
|
SECONDARY outcome
Timeframe: Week 8, Week 16, and Week 24Population: mITT population included all participants who took at least 1 dose of study drug and had at least 1 post-randomization visit that included evaluation of tender and swollen joints and at least 3 of other 5 variables required to calculate ACR50. LOCF method was used.
The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.
Outcome measures
| Measure |
Etanercept + Methotrexate
n=279 Participants
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate
n=142 Participants
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|
|
Change From Baseline in SF-36 Health Survey Social Functioning Domain Score at Week 8, Week 16, and Week 24
Week 8 (N: 278, 138)
|
1.51 units on a scale
Standard Error 0.12
|
0.77 units on a scale
Standard Error 0.15
|
|
Change From Baseline in SF-36 Health Survey Social Functioning Domain Score at Week 8, Week 16, and Week 24
Week 16 (N: 278, 138)
|
1.45 units on a scale
Standard Error 0.13
|
0.95 units on a scale
Standard Error 0.16
|
|
Change From Baseline in SF-36 Health Survey Social Functioning Domain Score at Week 8, Week 16, and Week 24
Week 24 (N: 278, 138)
|
1.60 units on a scale
Standard Error 0.12
|
0.82 units on a scale
Standard Error 016
|
Adverse Events
Etanercept + Methotrexate Phase 1
DMARD + Methotrexate Phase 1
Etanercept + Methotrexate Phase 2 Year 1
DMARD + Methotrexate Phase 2 Year 1
Etanercept + Methotrexate Phase 2 Year 2
DMARD + Methotrexate Phase 2 Year 2
Serious adverse events
| Measure |
Etanercept + Methotrexate Phase 1
n=281 participants at risk
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate Phase 1
n=143 participants at risk
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
Etanercept + Methotrexate Phase 2 Year 1
n=260 participants at risk
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate Phase 2 Year 1
n=126 participants at risk
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
Etanercept + Methotrexate Phase 2 Year 2
n=241 participants at risk
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate Phase 2 Year 2
n=120 participants at risk
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Atrial fibrillation
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Eye disorders
Ocular vascular disorder
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.83%
1/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Borderline serous tumour of ovary
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
General disorders
Device dislocation
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
General disorders
Oedema peripheral
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
General disorders
Pyrexia
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.83%
2/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Appendicitis
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.79%
1/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Bronchopneumonia
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Dengue fever
|
0.71%
2/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Latent tuberculosis
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Perirectal abscess
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Pneumonia
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Postoperative abscess
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Postoperative wound infection
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Septic shock
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.77%
2/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.70%
1/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Musculoskeletal and connective tissue disorders
Synovitis
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.79%
1/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.79%
1/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian adenoma
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.79%
1/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Nervous system disorders
Convulsion
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Nervous system disorders
Migraine with aura
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Pregnancy, puerperium and perinatal conditions
Abortion missed
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.83%
1/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
0.36%
1/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Renal and urinary disorders
Calculus urinary
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.70%
1/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Vascular disorders
Aortic aneurysm
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Vascular disorders
Hypertension
|
0.00%
0/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.38%
1/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
Other adverse events
| Measure |
Etanercept + Methotrexate Phase 1
n=281 participants at risk
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate Phase 1
n=143 participants at risk
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
Etanercept + Methotrexate Phase 2 Year 1
n=260 participants at risk
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate Phase 2 Year 1
n=126 participants at risk
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
Etanercept + Methotrexate Phase 2 Year 2
n=241 participants at risk
Phase 1: Etanercept 50 mg injection s.c. once weekly along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on etanercept and methotrexate, or a non-biologic DMARD the investigator preferred in accordance with the local label (SSZ or HCQ) could be added in exchange for or in addition to etanercept. Methotrexate could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
DMARD + Methotrexate Phase 2 Year 2
n=120 participants at risk
Phase 1: Conventional DMARD combination therapy (SSZ or HCQ) tablets administered as per local prescribing practice, along with methotrexate tablet (7.5-25 mg) orally once weekly either in single dose or in 2 divided doses for 24 weeks. Phase 2: During the optional Phase 2-period (week 24-week 128), the participants could remain on DMARD (SSZ or HCQ) and methotrexate, or a DMARD the investigator preferred in accordance with the local label (HCQ, SSZ, and/or etanercept) could be added in exchange for or in addition to the Phase 1 DMARD (SSZ or HCQ). Methotrexate and the DMARD administered in Phase 1 could be continued, discontinued or titrated. Phase 1 reporting groups were used also for Phase 2 data, regardless of the participant's Phase 2 treament regimen.
|
|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Dyspepsia
|
2.1%
6/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
6.3%
9/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.2%
3/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.6%
2/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.2%
3/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.00%
0/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Gastrointestinal disorders
Gastritis
|
1.8%
5/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
6.3%
9/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.9%
5/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.6%
2/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
2.5%
3/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Gastrointestinal disorders
Nausea
|
2.5%
7/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
9.1%
13/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.9%
5/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.2%
4/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.7%
4/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
2.5%
3/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Bronchitis
|
6.4%
18/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
2.1%
3/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.2%
11/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
7.9%
10/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
7.1%
17/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
2.5%
3/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Influenza
|
5.3%
15/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.2%
6/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.2%
11/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.2%
4/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.7%
9/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
5.0%
6/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Nasopharyngitis
|
5.0%
14/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.5%
5/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.2%
11/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
8.7%
11/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.6%
11/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.3%
4/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Infections and infestations
Urinary tract infection
|
2.8%
8/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.5%
5/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
3.8%
10/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.0%
5/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.6%
11/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
5.0%
6/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
2.8%
8/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
2.1%
3/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.9%
5/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.79%
1/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
1.2%
3/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
5.0%
6/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
|
Nervous system disorders
Headache
|
3.9%
11/281 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
7.0%
10/143 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
2.7%
7/260 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
4.0%
5/126 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.41%
1/241 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
0.83%
1/120 • Phase 1: Baseline-Week 26 (Follow up telephone visit), Phase 2 Year 1: Week 24-Week 76, Phase 2 Year 2: Week 76-Week 128
The same event may appear as both an AE and a SAE. DMARD + methotrexate included 143 rather than 142 participants as reported in the Phase 1 CSR. One participant was originally excluded from evaluation for no record of dosing, however 4 days of study medication was later reported.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER